Fatty liver showdown: which pill reduces fat better?
NCT ID NCT07194863
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tests two treatments—essential phospholipid and betaine HCL/L-glutamic acid—in 200 adults with metabolic fatty liver disease (MAFLD). The goal is to see which one better reduces liver fat over the treatment period. Participants must be over 18 and diagnosed with fatty liver; those with certain conditions or on specific medications cannot join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL PHOSPHOLIPID IN METABOLIC ASSOCIATED FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.